Although the FDA approval of daratumumab and hyaluronidase-fihj (subcutaneous daratumumab; Darzalex Faspro) offers a treatment option for patients with high-risk smoldering multiple myeloma, the decision to start treatment ahead of active multiple…
FDA Approval of Daratumumab Opens Treatment Options for High-Risk Smoldering Myeloma
